Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.17M | 6.15M | -72.70M | -119.39M | -130.41M |
| Total Depreciation and Amortization | 10.63M | 10.18M | 10.23M | 9.62M | 9.25M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.04M | 12.67M | 13.07M | 13.03M | 13.91M |
| Change in Net Operating Assets | -20.12M | 5.66M | 91.40M | 39.45M | 46.25M |
| Cash from Operations | 27.72M | 34.67M | 42.00M | -57.29M | -61.00M |
| Capital Expenditure | -3.86M | -4.19M | -3.99M | -5.49M | -6.75M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.19M | -150.34M | -40.46M | 6.24M | 5.37M |
| Cash from Investing | -68.05M | -154.53M | -44.45M | 741.00K | -1.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.00M | 55.30M | 55.53M | 52.21M | 53.30M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.00M | 43.36M | 43.36M | 71.24M | 71.24M |
| Cash from Financing | 1.00M | 98.66M | 98.89M | 123.46M | 124.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.33M | -21.21M | 96.44M | 66.91M | 62.16M |